Clinical Trials

Inclusion Criteria:

• Histologically confirmed newly diagnosed glioblastoma (WHO Grade IV).

• IDH-wildtype status confirmed by molecular testing.

• Age ≥ 18 years at the time of consent.

• Karnofsky Performance Status (KPS) ≥70 at baseline.

• Adequate organ and marrow function, defined as:

  • Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L

  • Platelet count ≥100 × 10⁹/L

  • Hemoglobin ≥9 g/dL

  • Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min

  • AST and ALT ≤2.5 × ULN

  • Total bilirubin ≤1.5 × ULN

• Willingness and ability to comply with CGM device use and attend dietary counseling sessions as part of the study protocol.

Exclusion Criteria:

• Recurrent glioblastoma or prior therapy for glioblastoma beyond surgical resection or biopsy.

• History of eating disorders (e.g., anorexia nervosa, bulimia) or substance use disorder within the past 12 months.

• Any other uncontrolled or inadequately managed medical illness (e.g., unstable cardiovascular, hepatic, renal, or psychiatric condition) that, in the opinion of the investigator, would interfere with study participation or interpretation of results.

• Concurrent diagnosis of another active malignancy requiring treatment.

• Pregnancy or breastfeeding at the time of enrollment.

• Documented history of Type 1 Diabetes Mellitus.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/04/2025. Questions regarding updates should be directed to the study team contact.